Download PDF
Thromb Haemost 1993; 70(06): 0903-0908
DOI: 10.1055/s-0038-1649697
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Antithrombotic Activity of Bay u3405, a Thromboxane A2-Antagonist, in Patients with Dacron Aortic Grafts: a Random Controlled Clinical Trial

H Pieters
1   The Department of Haematology, University of the Orange Free State, Bloemfontein, South Africa
,
J P Roodt
1   The Department of Haematology, University of the Orange Free State, Bloemfontein, South Africa
,
P N Badenhorst
1   The Department of Haematology, University of the Orange Free State, Bloemfontein, South Africa
,
V van Wyk
1   The Department of Haematology, University of the Orange Free State, Bloemfontein, South Africa
,
R Schall
2   The Department of Pharmacology, University of the Orange Free State, Bloemfontein, South Africa
,
M G Lötter
3   The Department of Biophysics, University of the Orange Free State, Bloemfontein, South Africa
,
H K L Hundt
2   The Department of Pharmacology, University of the Orange Free State, Bloemfontein, South Africa
,
C J C Nel
4   The Department of Surgery, University of the Orange Free State, Bloemfontein, South Africa
› Author Affiliations
Further Information

Publication History

Received 11 February 1993

Accepted after revision 30 July 1993

Publication Date:
06 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Twelve patients with Dacron aortic grafts participated in a placebo controlled, crossover trial to investigate the effect of Bay u3405, a thromboxane A2-receptor antagonist, on graft throm-bogenicity. During each treatment period (seven days, Bay u3405 or placebo), 111In-platelet survival and platelet deposition on the grafts were measured daily by γ-camera imaging and blood radioactivity analysis. Bay u3405 substantially reduced the deposition of platelets and the thrombogenic index, while platelet survival remained unchanged. The ex vivo platelet aggregation response to ADP and epinephrine was significantly inhibited. The bleeding time increased slightly but not to any clinically relevant extent, and no adverse side effects were recorded.

Bay u3405 seems to be a safe and effective drug for the inhibition of platelet deposition on aortic Dacron grafts. The use of quantitative imaging techniques is also more sensitive than the measurement of platelet survival for the assessment of antiplatelet drug efficacy in patients with aortic grafts.

 

  • References

  • 1 Harker LA, Slichter SJ, Sauvage JR. Platelet consumption by arterial prostheses: the effect of endothelialization and pharmacologic inhibition of platelet function. Ann Surg 1977; 186: 560-594
    PubMedGoogle Scholar
  • 2 McCollum CN, Kester RC, Rajah SM, Learoyd P, Pepper M. Arterial graft maturation: the duration of thrombotic activity in Dacron aortobifemoral grafts measured by platelet and fibrinogen kinetics. Br J Surg 1981; 68: 61-64
    CrossrefPubMedGoogle Scholar
  • 3 Stratton JR, Thiele BL, Ritchie JL. Platelet deposition on Dacron aortic bifurcation grafts in man: quantitation with indium-111 platelet imaging. Circulation 1982; 66: 1287-1293
    CrossrefPubMedGoogle Scholar
  • 4 Goldman M, Norcott HC, Hawker RJ, Drolc Z, McCollum CN. Platelet accumulation on mature Dacron grafts in man. Br J Surg 1982; 69 (Suppl) S38-S40
    CrossrefPubMedGoogle Scholar
  • 5 Goldman M, Hail C, Dykes J, Hawker RJ, McCollum CN. Does 111-indium platelet deposition predict patency in prosthetic arterial grafts. Br J Surg 1983; 70: 635-638
    CrossrefPubMedGoogle Scholar
  • 6 Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M. Pharmacological actions of SQ29548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 1985; 234: 435-441
    PubMedGoogle Scholar
  • 7 Ashton JH, Schmitz JM, Campbell WB, Ogletree ML, Raheja S, Taylor AL, Fitzgerald C, Buja LM, Willerson JT. Inhibition of cyclic flow variations in stenosed canine arteries by thromboxane A2/prostaglandin H2receptor antagonists. Circ Res 1986; 59: 568-578
    CrossrefPubMedGoogle Scholar
  • 8 Hanasaki K, Arita H. Characterization of a new compound, S-145, as a specific TXA2receptor antagonist in platelets. Thromb Res 1988; 50: 365-376
    CrossrefPubMedGoogle Scholar
  • 9 Perzbom E, Seuter F, Fiedler VB, Rosentreter U, Böshagen H. Action of the selective thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-l,2,3,4-tetrahydro-9-carbazolepropanoic acid on vascular smooth muscle preparations. Arzneimittelforschung 1989; 39: 1522-1525
    PubMedGoogle Scholar
  • 10 Seuter F, Perzborn E, Rosentreter U, Böshagen H, Fiedler VB. Inhibition of platelet aggregation in vitro and ex vivo by the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-l,2,3,4-tetrahydro-9-carbazolepropanoic acid. Arzneimittelforschung 1989; 39: 1525-1527
    PubMedGoogle Scholar
  • 11 Theis JGW, Dellweg H, Perzborn E, Gross R. Binding characteristics of the new thromboxane A2/prostaglandin H2receptor antagonist [3H]BAY u3405 to washed human platelets and platelet membranes. Biochem Pharmacol 1992; 44: 495-503
    CrossrefPubMedGoogle Scholar
  • 12 Kotzè HF, Heyns AduP, Lotter MG, Pieters H, Roodt JP, Sweetlove MA, Badenhorst PN. Comparison of oxine and tropolone methods for labelling human platelets with Indium-111. J Nucl Med 1991; 32: 62-66
    PubMedGoogle Scholar
  • 13 I.C.S.H. Internal committee for standardisation in haematology;. Panel on diagnostic applications of radionuclides. Recommended method for Indium-111 platelet survival studies. J Nucl Med 1988; 29: 5641-5646
    PubMedGoogle Scholar
  • 14 Heyns AduP, Lötter MG, Badenhorst PN. Platelet Imaging. In: Measurements of platelet function. Harker LA, Zimmerman TS. (eds). London: Churchill Livingstone; 1983: 216-234
    Google Scholar
  • 15 Hundt HKL, Joubert AL. Determination of Bay u3405 in plasma by HPLC and UV detection. 1993 (unpublished)
    PubMedGoogle Scholar
  • 16 Lötter MG, Heyns AduP, Badenhorst PN, Wessels P, van ZylMJ, Kotzé HF, Minnaar PC. Evaluation of mathematical models to assess platelet kinetics. J Nucl Med 1986; 27: 1192-1201
    PubMedGoogle Scholar
  • 17 van RensburgAJ, Lötter MG, Heyns AduP, Minnaar PC. An evaluation of four methods of 111-In planar image quantification. Med Phys 1988; 15: 853-861
    CrossrefPubMedGoogle Scholar
  • 18 Hanson SR, Kotzè HF, Pieters H, Heyns AduP. Analysis of Indium-111 platelet kinetics and imaging in patients with aortic grafts and abdominal aortic aneurysms. Arteriosclerosis 1990; 10: 1037-1044
    CrossrefPubMedGoogle Scholar
  • 19 Mortelmans L, Verbruggen A, de BakkerL, Vandecruys A, Joosten J, Nevelsteen A, Noyez L, Verstraete M, Vermylen J, de RooM. Comparison of quantification methods of 111-In-labelled platelet deposition in peripheral bypass grafts. Nuklearmedizin 1987; 26: 87-92
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Goldman M, Norcott HC, Hawker RJ, Hail C, Drolc Z, McCollum CN. Femoropopliteal bypass grafts – an isotope technique allowing in vivo comparison of thrombogenicity. Br J Surg 1982; 69: 380-382
    CrossrefPubMedGoogle Scholar
  • 21 Goldman M. Clinical studies with 111-In-labelled platelets. Nucl Med Commun 1988; 69: 809-812
    PubMedGoogle Scholar
  • 22 Wessels P, Heyns AduP, Pieters H, lötter MG, Badenhorst PN. An improved method for the quantification of the in vivo kinetics of a representative population of In-Ill-labelled human platelets. Eur J Nucl Med 1985; 10: 522-527
    PubMedGoogle Scholar
  • 23 Lötter MG. Measurement of platelet survival and analysis of survival curves. In: Platelet kinetics and imaging. Heyns AP, Badenhorst PN, Lötter MG. eds. BocaRaton, USA: CRC Press Inc.; 1985: 35-72
    Google Scholar
  • 24 Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974; 2: 924-926
    PubMedGoogle Scholar
  • 25 Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. B M J 1986; 292: 746-750
    CrossrefPubMedGoogle Scholar
  • 26 Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharm Ther Tox 1990; 28: 72-78
    PubMedGoogle Scholar
  • 27 Kester RC. The thrombogenicity of Dacron arterial grafts and its modification by platelet inhibitory drugs. Ann R Coll Surg Engl 1984; 66: 241-246
    PubMedGoogle Scholar
  • 28 Hake U, Gabbert H, Iversen S, Jakob H, Schmiedt W, Oelert H. Healing parameters of a new albumin-coated knitted Dacron graft. Thorac Cardiovasc Surg 1991; 39: 208-213
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Hanson SR, Reidy MA, Hattori A, Harker LA. Pharmacologic inhibition of acute vascular graft thrombosis. Scanning Electron Microscopy 1982; 2: 773-739
    PubMedGoogle Scholar
  • 30 LoGerfo FW. The blood-materials interaction and downstream effects in prosthetic conduits. J Vase Surg 1991; 13: 740-742
    CrossrefPubMedGoogle Scholar
  • 31 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin 1-D-phenylalanyl-L-prolyl-L-argenyl chloromethylketone (FPRCH2C1). Proc Natl Acad Sci USA 1988; 85: 3184-3188
    CrossrefPubMedGoogle Scholar
  • 32 Kotzè HF, Lumsden A, Harker LA, Hanson SR. In vivo antithrombin effects of local versus systemic therapy with potent antithrombins. Circulation 1990; 82: 603 (Abstract)
    PubMedGoogle Scholar
  • 33 Hanson SR. Platelet-specific antibodies as in vivo therapeutic reagents: a baboon model. In: Platelet Immunobiology: Molecular and Clinical Aspects. Kunicki TJ, George JN. eds. Philadelphia: JB Lippincott Company; 1989: 471-483
    Google Scholar
  • 34 Hanson SR, Kotzè HF, Harker LA, Scarborough RM, Charo IF, Phillips DR. Potent antithrombotic effects of novel peptide antagonists of platelet glycoprotein (GP) IIb/IIIa . Thromb Haemostas 1991; 65: 813 (Abstr).
    PubMedGoogle Scholar
  • 35 Badenhorst PN, Kotzè HF, Lambrecht S, Meiring SM, Van WykV, Deckmyn H. Dose-dependent inhibition of acute arterial thrombosis by monoclonal antibody 16N7C2 in a baboon model. Revista de Espanola Medicine Nuclear 1992; 11: 66 (Abstr).
    PubMedGoogle Scholar
  • 36 Sheehan SJ, Monson JRT, Salter MCP, Rajah DS, Rajah SM, Kester RC. The effect of indobufen on the thrombogenic potential of a Dacron prosthesis in an artificial circulation. Eur J Vase Surg 1988; 2: 223-227
    CrossrefPubMedGoogle Scholar
  • 37 Bech FR, Cronenwett JL, McDaniel MD, Ogletree ML, Freeman DH. The effect of thromboxane receptor blockade versus thromboxane synthase inhibition on canine graft patency. J Vase Surg 1990; 12: 119-125
    CrossrefPubMedGoogle Scholar
  • 38 Nevelsteen A, Mortelmans L, van deCruys A, Merckx E, Verhaege R. Effect of ticlopidine on blood loss, platelet turnover and platelet deposition on prosthetic surfaces in patients undergoing aorto-femoral bypass grafting. Thromb Res 1991; 64: 363-369
    CrossrefPubMedGoogle Scholar
  • 39 Stratton JR, Ritchie JL. Reduction of indium-111 platelet deposition on Dacron vascular grafts in humans by aspirin plus dipyridamole. Circulation 1986; 73: 325-330
    CrossrefPubMedGoogle Scholar
  • 40 Callow AD, Connolly R, O’Donnell Jr TF, Gembarowiez R, Keough E, Ramberg-Laskaris K, Valeri CR. Platelet-arterial synthetic graft interactions and its modification. Arch Surg 1982; 117: 1447-1455
    CrossrefPubMedGoogle Scholar
  • 41 Mackey WC, Connolly RJ, Callow AD, Keough EM, Ramberg-Laskaris K, McCullough JL, O’Donnell Jr TF, Melaragno A, Valeri CR, Weiblen B. Aspirin decreases platelet uptake on Dacron vascular grafts in baboons. Ann Surg 1984; 200: 93-99
    CrossrefPubMedGoogle Scholar
  • 42 Mann KG, Tracey PB, Nesheim ME. Assembly and function of prothrombinase complex on synthetic and natural membranes. In: Interaction of platelets with the vessel wall. Oates JA, Hawiger J, Ross R. eds. Baltimore: Waverly Press Inc; 1985: 47-57
    Google Scholar
  • 43 Kotzè HF, Heyns AduP, Nel CJC, Roodt JP, Herbst CP, Badenhorst PN, lötter MG. The influence of platelet-graft interaction on platelet survival in patients with aortobifemoral Dacron grafts. S Afr Med J 1992; 81: 27-30
    PubMedGoogle Scholar
  • 44 Kotzè HF, Pieters H, Heyns AduP, Badenhorst PN, Lötter MG, Nel CJC. Quantification of the thrombogenicity of Dacron aortic prostheses. S Afr J Surg 1986; 24: 65-68
    PubMedGoogle Scholar
  • 45 Lane IF, Lumley P, Michael MF, Peters AM, McCollum CN. A specific thromboxane receptor blocking drug, AH23848, reduces platelet deposition on vascular grafts in man. Thromb Haemostas 1990; 64: 369-373
    PubMedGoogle Scholar
  • 46 Stratton JR, Ritchie JL. Failure of ticlopidine to inhibit deposition of indium-Ill-labeled platelets on Dacron prosthetic surfaces in humans. Circulation 1984; 69: 677-683
    CrossrefPubMedGoogle Scholar
  • 47 Stratton JR, Ritchie JL. Effect of suloctidil on tomographically quantitated platelet accumulation in Dacron aortic grafts. Am J Cardiol 1986; 58: 152-156
    CrossrefPubMedGoogle Scholar
  • 48 Stratton JR, Ritchie JL. The effect of sulfinpyrazone on platelet deposition on Dacron vascular grafts in man. Am Heart J 1985; 109: 453-457
    CrossrefPubMedGoogle Scholar
  • 49 Ma X, Karasawa A, Lefre AM. Mechanism of the protective effect of Bay u3405, a new specific thromboxane receptor antagonist, in arachidonate-induced sudden death. Meth Find Exp Clin Pharmacol 1991; 13: 105-110
    PubMedGoogle Scholar